Literature DB >> 32125520

Patient reported outcome measures (PROMs) in amyotrophic lateral sclerosis.

Fabiola De Marchi1, James D Berry1, James Chan2, Sarah Caldwell1, Amy Ellrodt1, Jennifer Scalia1, Katherine Burke1, Ton Fang1, Rachel Clark Sisodia3, Lee H Schwamm4, Lidia M V R Moura4, Sabrina Paganoni5,6.   

Abstract

OBJECTIVE: Patient reported outcome measures (PROMs) can provide researchers with a direct view of patients' experiences. They are becoming increasingly important tools for evaluating clinical care and research outcomes. There has been little data on the application of PROMs to amyotrophic lateral sclerosis (ALS) care. The objective of this study was to examine the feasibility of PROM collection in an academic ALS clinic and to measure correlations between PROMs and standard ALS clinical outcome measures.
METHODS: PROMs were gathered from tablet-based surveys offered to adult patients in the waiting room, prior to ALS outpatient clinic visits. They included a demographic section and two validated surveys: the patient reported outcome measurement information system (PROMIS-10), which generates physical health and mental health subscores, and the quality of life in neurological disorders-fatigue subscale (NeuroQoL-fatigue). The ALS functional rating scale-revised (ALSFRS-R) and other ALS measures were collected by clinic staff as part of routine clinical care.
RESULTS: PROMIS-10 physical and mental health scores correlated positively with the ALSFRS-R score (physical: R = 0.85, p < 0.001; mental: R = 0.58, p = 0.02). NeuroQoL-fatigue scores were inversely correlated with the ALSFRS-R scores-higher fatigue correlated with lower function (R = - 0.72, p = 0.004).
CONCLUSION: Collection of PROMs is feasible in the context of routine ALS care. PROM scores are highly correlated with validated ALS outcome measures.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Measures; Neurology; Outcome; PROMs

Year:  2020        PMID: 32125520     DOI: 10.1007/s00415-020-09774-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  3 in total

1.  Changes in the normal maximal expiratory flow-volume curve with growth and aging.

Authors:  R J Knudson; M D Lebowitz; C J Holberg; B Burrows
Journal:  Am Rev Respir Dis       Date:  1983-06

Review 2.  Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease.

Authors:  Chris Gibbons; Francesco Pagnini; Tim Friede; Carolyn A Young
Journal:  Cochrane Database Syst Rev       Date:  2018-01-02

3.  Quantitative strength testing in ALS clinical trials.

Authors:  Jeremy M Shefner; Dawei Liu; Melanie L Leitner; David Schoenfeld; Donald R Johns; Toby Ferguson; Merit Cudkowicz
Journal:  Neurology       Date:  2016-07-06       Impact factor: 9.910

  3 in total
  4 in total

1.  Using patient-reported symptoms of dyspnea for screening reduced respiratory function in patients with motor neuron diseases.

Authors:  Jochem Helleman; Esther T Kruitwagen-van Reenen; J Bakers; Willeke J Kruithof; Annerieke C van Groenestijn; Rineke J H Jaspers Focks; Arthur de Grund; Leonard H van den Berg; Johanna M A Visser-Meily; Anita Beelen
Journal:  J Neurol       Date:  2020-06-23       Impact factor: 4.849

2.  Fatigue in Chinese Patients With Amyotrophic Lateral Sclerosis: Associated Factors and Impact on Quality of Life.

Authors:  Ran An; Cheng Li; Xin Li; Yuan Wu; Xianghua He; Shaolong Ai; Yanming Xu; Chengqi He
Journal:  Front Neurol       Date:  2022-02-18       Impact factor: 4.003

3.  The 6-min walk test as a new outcome measure in Amyotrophic lateral sclerosis.

Authors:  Massimo Russo; Christian Lunetta; Riccardo Zuccarino; Gian L Vita; Maria Sframeli; Andrea Lizio; Stefania La Foresta; Cristina Faraone; Valeria A Sansone; Giuseppe Vita; Sonia Messina
Journal:  Sci Rep       Date:  2020-09-23       Impact factor: 4.379

Review 4.  Qualitative measures that assess functional disability and quality of life in ALS.

Authors:  Susan L Hartmaier; Thomas Rhodes; Suzanne F Cook; Courtney Schlusser; Chao Chen; Steve Han; Neta Zach; Venkatesha Murthy; Shreya Davé
Journal:  Health Qual Life Outcomes       Date:  2022-01-21       Impact factor: 3.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.